<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393857</url>
  </required_header>
  <id_info>
    <org_study_id>Microbiome_endometrial_spain</org_study_id>
    <nct_id>NCT04393857</nct_id>
  </id_info>
  <brief_title>The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in Oocyte Donors</brief_title>
  <official_title>The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in Oocyte Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Humaidan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to examine the endometrium with state of the art sequencing techniques&#xD;
      to investigate the endometrial microbiota. The endometrial microbiota has been perceived to&#xD;
      be sterile, however, this seems incorrect from recent studies. Thus, the primary outcome is&#xD;
      to compare the rate of ascending infection from the vagina to the endometrium and to&#xD;
      investigate which bacteria are capable of inhabiting these environments in healthy oocyte&#xD;
      donors. These results will be compared to equivalent samples of IVF patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ascending infection/sharing of bacteria in the genital tract</measure>
    <time_frame>This outcome data is measured at the 1 day of oocyte retrieval.</time_frame>
    <description>vaginal, cervical and endometrial samples will be compared at the time of oocyte retrieval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Next generation sequencing techniques and qPCR will be used to assess the microbiota.I.e. measure of relative abundances and absolute abundances</measure>
    <time_frame>This outcome data is measured at the 1 day of oocyte retrieval.</time_frame>
    <description>qPCR to assess the microbiota. I.e. a quantitative measure Copies/mL. 16S V4 to investigate relative abundances</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Oocyte donors</arm_group_label>
    <description>Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Vaginal, Cervical and endometrial samples taken with the Eswab (Copan), eNAT (Copan) and Tao&#xD;
      brush (Cook medical). Although there will be Human DNA in samples, we aim to isolate&#xD;
      bacterial DNA for further analysis. No analyses are planned on Human DNA.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy oocyte donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Oocyte donors meeting local criteria for donation. Written informed consent. Regular cycle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Antibiotics within 1 month Vaginal products other than for menstrual hygiene within 1 month&#xD;
        Uterine malformations(Septum, polyps, adenomyosis, fibroids) HIV, Hepatitis B or C&#xD;
        positivity. HPV CIN 2 or higher. Chlamydia trachomatis positivity.&#xD;
&#xD;
        Any uncontrolled concomitant disease (e.g. uncontrolled diabetes, uncontrolled hypertension&#xD;
        etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>Professor, Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>WE plan to share all information allowed as per national law.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

